Compare LAES & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAES | BNTC |
|---|---|---|
| Founded | 2022 | 1995 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 821.2M | 411.4M |
| IPO Year | 2022 | 2020 |
| Metric | LAES | BNTC |
|---|---|---|
| Price | $2.49 | $10.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $4.00 | ★ $27.67 |
| AVG Volume (30 Days) | ★ 6.5M | 135.9K |
| Earning Date | 03-31-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $93.36 | N/A |
| Revenue Next Year | $43.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.12 | $9.85 |
| 52 Week High | $8.71 | $17.15 |
| Indicator | LAES | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 30.93 | 47.24 |
| Support Level | N/A | $9.89 |
| Resistance Level | $2.88 | $13.27 |
| Average True Range (ATR) | 0.23 | 0.59 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 20.43 | 41.99 |
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.